Namirotene (CBS 211A) is a protein biosynthesis inhibitor, a synthetic retinoic acid analog that is used in the study of corneal diseases, corneal ulcers and dry eye syndrome.

JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.

Gefarnate is a synthetic compound used for the treatment of gastric ulcers,and also used in the treatment of dry eye syndrome.

Tivanisiran (SYL1001) is a siRNA developed specifically to inhibit the expression of transient receptor potential vanilloid 1 (TRPV1) to explore its implications in dry eye disease research.

Immune cell migration-IN-2 is a potent inhibitor of immune cell migration, exhibiting an EC50 value of 13.5 nM in a T-cell adhesion assay. This compound is utilized in research pertaining to dry-eye and other retinal diseases [1]. As a click chemistry reagent, Immune cell migration-IN-2 possesses an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules.

Immune cell migration-IN-1 (compound 2) serves as a potent inhibitor of immune cell migration, with potential research applications for mitigating conditions such as dry eye diseases, eczema dermatitis, and psoriasis [1].

Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.

Simpinicline (OC-02) (OC-02) is a highly selective nicotinic acetylcholine receptor (nAChR) agonist that activates the trigeminal parasympathetic pathway and can be used to treat dry eye.

Diquafosol Tetrasodium is a P2Y2 receptor agonist that stimulates the secretion of mucins from ocular tissues Diquafosol tetrasodium (INS365) improves tear film stability and visual function, as a topical treatment of dry eye disease.

Fluorometholone (Fluoromethalone) is a corticosteroid, most often used after laser-based refractive surgery. It is marketed under the brand names FML (Allergan) and Flarex (Alcon). Fluorometholone acetate ophthalmic suspension is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Navamepent (RX-10045) is an analog of resolvin E1 (a dietary-3 polyunsaturated fatty acid metabolite), which has potent anti-inflammatory activity that reduces corneal inflammation, epithelial damage, and accelerates corneal tissue repair.Navamepent inhibits the release of several key pro-inflammatory mediators from corneal epithelial cells.Navamepent is very effective against dry eye and cupping cell loss Navamepent is effective against dry eye and cupping cell loss, and accelerates tear production.

TOP1362 is a Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. TOP1362 strongly inhibited the kinase targets p38α, Syk, Src, and Lck, blocked the rise in p38α expression in hyperosmolar Chang cells, and potently reduced inflammatory cytokine release in cellular models of innate and adaptive immunities. In the EIU model, TOP1362 dose-dependently attenuated the LPS-induced rise in inflammatory cell infiltration and ocular cytokine levels with efficacy comparable to that of dexamethasone.

Tanfanercept (HL036337), an anti-TNF-α monoclonal antibody, has shown efficacy in reducing corneal erosions in a dry eye (DE) mouse model [1] [2].

Reproxalap (NS-2) covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal. Reproxalap is a reactive aldehyde species sequestering agent for the treatment of the dry eye.

Icomucret can be used for the Treatment of Dry Eye.

R-932348 choline, a dual JAK/SYK inhibitor, is used potentially for treatment of dry eye disease.

Lifitegrast (SAR 1118) is a lymphocyte, function-associated antigen-1 antagonist.

JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2. The compound has been identified as having research potential for the treatment of dry eye disease (DED) [1].